Delee
Mexico City, Mexico· Est.
Delee delivers an automated, high‑recovery CTC isolation and analysis platform for oncology diagnostics and research.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Delee delivers an automated, high‑recovery CTC isolation and analysis platform for oncology diagnostics and research.
Oncology
Technology Platform
CytoCatch™ combines microfluidic CTC capture with AI‑driven imaging and customizable fluorescence panels for automated isolation, enumeration, and downstream molecular analysis.
Opportunities
Regulatory clearance and partnerships with diagnostic labs could unlock rapid adoption in oncology clinical trials and precision‑medicine programs.
Risk Factors
Dependence on regulatory approvals and competition from established liquid‑biopsy platforms may delay market penetration.
Competitive Landscape
Delee competes with CellSearch, Rarecyte, and Celsee but differentiates through higher recovery rates, full automation, and a customizable antibody framework.